Výsledky vyhledávání

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

Autor: G. Cohen, Stephen E. Jones, James Hackett, John A. Glaspy, Donald A. Richards, T. George, Frankie A. Holmes, Michael Savin, Joyce A. O'Shaughnessy, S. Vukelja, M. Dhami, D. R. Budman, M. Brassard, L. Meza, B. B. Yang, B. C. Liang

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 13(6)

Background Neutropenia is common in patients receiving myelotoxic chemotherapy. Pegfilgrastim, a sustained-duration filgrastim is a once-per-cycle therapy for prophylactic neutrophil support. Patients and methods Women, treated with four cycles of do

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4eacf80983ab06040507cb6d40c119f
https://pubmed.ncbi.nlm.nih.gov/12123336

Zobrazit plný text záznamu

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

Autor: D R, Budman, D A, Berry, C T, Cirrincione, I C, Henderson, W C, Wood, R B, Weiss, C R, Ferree, H B, Muss, M R, Green, L, Norton, E, Frei

Publikováno v: Journal of the National Cancer Institute. 90(16)

Both total dose and dose intensity of adjuvant chemotherapy are postulated to be important variables in the outcome for patients with operable breast cancer. The Cancer and Leukemia Group B study 8541 examined the effects of adjuvant treatment using

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5a7a1af83718bf58b7a35eec0f34583d
https://pubmed.ncbi.nlm.nih.gov/10451457

Zobrazit plný text záznamu

Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells

Autor: L G, Wang, X M, Liu, W, Kreis, D R, Budman

Publikováno v: Cancer research. 57(4)

As a specific competitive inhibitor of 5alpha-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone, finasteride is being extensively used for the treatment of benign prostatic hyperplasia and in experimental settings f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4444131c06c333f1bed5e05fa93dc7ea
https://pubmed.ncbi.nlm.nih.gov/9044850

Zobrazit plný text záznamu

Early studies of etoposide phosphate, a water-soluble prodrug

Autor: D R, Budman

Publikováno v: Seminars in oncology. 23(6 Suppl 13)

Etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) is a water-soluble prodrug of etoposide that is converted in vivo by endogenous phosphatases to the active drug etoposide. This conversion process is efficient and not satur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::24f483517b617ca8c0aa43b82a3b0acb
https://pubmed.ncbi.nlm.nih.gov/8996570

Zobrazit plný text záznamu

Phase I study of high-dose etoposide phosphate in man

Autor: S Z, Fields, D R, Budman, R R, Young, W, Kreis, R, Ingram, P, Schulman, R C, Cherny, J, Wright, J, Behr, C, Snow, L P, Schacter

Publikováno v: Bone marrow transplantation. 18(5)

Etoposide is a widely used cytotoxic agent with a broad spectrum of activity in human malignancies. This agent has been incorporated into many transplant regimens although toxicity occurs because of its poor water solubility and toxic excipients. Eto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c06f3bb565b1cfeff1cbe7578ee2cbc2
https://pubmed.ncbi.nlm.nih.gov/8932836

Zobrazit plný text záznamu

Pharmacokinetic evaluation of zeniplatin in humans

Autor: L. C. De Marco, D. R. Budman, C. Lathia, P. Amorusi, M. Birkhofer, S. Lichtman, L. Weiselberg, V. Vinciguerra, J. Lovecchio, D. Gal, A. Hoffman, J. Kantrowitz, R. Rastogi

Publikováno v: Cancer chemotherapy and pharmacology. 36(1)

Zeniplatin, a more water-soluble organoplatinum than cisplatin, was evaluated for clinical pharmacology in the context of a phase II trial in previously treated patients with ovarian carcinoma. A total of 12 patients were given zeniplatin at 120 mg/m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1471bac3bfd290fe204c8774c9bc78ce
https://pubmed.ncbi.nlm.nih.gov/7720173

Zobrazit plný text záznamu

Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study

Autor: W, Kreis, D R, Budman, K, Chan, S L, Allen, P, Schulman, S, Lichtman, L, Weiselberg, M, Schuster, J, Freeman, S, Akerman

Publikováno v: Leukemia. 5(11)

Thirty two patients with refractory or recurrent acute leukemia or blast crisis of chronic myelocytic leukemia were treated with 1-beta-D-arabinofuranosylcytosine (Ara-C), 100 mg/m2 [group I (n = 15)] or 200 mg/m2 [group II (n = 18)], and tetrahydrou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8b4c63b049c69b6779baaca0ffefa8fb
https://pubmed.ncbi.nlm.nih.gov/1961042

Zobrazit plný text záznamu

Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study

Autor: J, Cuttner, R, Mick, D R, Budman, R J, Mayer, E J, Lee, E S, Henderson, R B, Weiss, P A, Paciucci, R, Sobol, F, Davey

Publikováno v: Leukemia. 5(5)

This paper reports a study of the Cancer and Leukemia Group B (CALGB) comparing daunorubicin (DNR) or mitoxantrone (DHAD) in induction followed by multidrug intensification over 8 months in adult patients with acute lymphocytic leukemia (ALL). A tota

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7ae4c797b828618a20660ae0af0d7bf9
https://pubmed.ncbi.nlm.nih.gov/2033963

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání